Innoviva, INC 10-K annual reports

Innoviva, Inc. filed an amended annual report to include the audited financial statements of its subsidiary, Armata Pharmaceuticals, Inc., which reported substantial losses and a going concern doubt.

Innoviva reports significant revenue growth in 2025 driven by strong product sales and strategic investments, despite a slight dip in royalty revenue.

Innoviva, Inc. files an amendment to its 2024 annual report to include the audited consolidated financial statements of Armata Pharmaceuticals, Inc.

Innoviva's 2024 results show increased product sales offset by equity investment losses, while the company advances its pipeline with a planned NDA submission for Zoliflodacin.

Innoviva Inc. has filed an amendment to its annual report to include the audited financial statements of Armata Pharmaceuticals, Inc., a company in which it holds a significant stake.

Innoviva files an amendment to its 2023 annual report to correct a clerical error in the audit report, while also providing detailed financial results for the year.

Innoviva, Inc. reports its 2023 financial results, showcasing a significant transformation driven by strategic acquisitions and a focus on shareholder value.